These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21624491)

  • 1. Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial.
    Magnussen H; Watz H; Kirsten A; Wang M; Wray H; Samuelsson V; Mo J; Kay R
    Pulm Pharmacol Ther; 2011 Oct; 24(5):563-70. PubMed ID: 21624491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.
    Dahl R; Titlestad I; Lindqvist A; Wielders P; Wray H; Wang M; Samuelsson V; Mo J; Holt A
    Pulm Pharmacol Ther; 2012 Apr; 25(2):169-77. PubMed ID: 22306193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.
    Kerstjens HA; Bjermer L; Eriksson L; Dahlström K; Vestbo J
    Respir Med; 2010 Sep; 104(9):1297-303. PubMed ID: 20466530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
    Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
    COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
    Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
    Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.